Key insights
- Intellia Therapeutics' Phase 3 trial for its HAE therapy, lonvo-z, met its primary and secondary endpoints, showing an 87% reduction in attacks compared to placebo. The company has initiated a rolling BLA submission with the FDA, anticipating a potential US launch in H1 2027. Analyst revisions are positive, and the stock is considered undervalued. This positive news could boost investor confidence in the biotech sector.
CAMBRIDGE, Mass. - Intellia Therapeutics Inc. (NASDAQ:NTLA) announced today that its Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met its primary and all key secondary endpoints for treating hereditary angioedema.
The trial enrolled 80 patients, with 52 receiving a single 50 milligram dose of lonvo-z and 28 receiving placebo. The treatment reduced attacks by 87% versus placebo during the six-month efficacy evaluation period, with a mean monthly attack rate of 0.26 compared with 2.10 in the placebo arm.
The trial met all key secondary endpoints. Sixty-two percent of patients in the lonvo-z arm were entirely attack-free and therapy-free during the six-month period, compared with 11% in the placebo arm.The positive results come as Intellia, with a market cap of $1.61 billion, has seen its stock surge 64% over the past year despite recent volatility. According to InvestingPro data, five analysts have revised their earnings upwards for the upcoming period, with price targets ranging from $5 to $106.
The most common treatment emergent adverse events during the primary observation period were infusion-related reactions, headache and fatigue. All adverse events reported as of the February 10, 2026 data cutoff were mild or moderate, with no serious adverse events observed in the lonvo-z arm.
Lonvo-z is an in vivo CRISPR gene editing candidate designed to inactivate the kallikrein B1 gene to lower kallikrein and bradykinin levels. The treatment is administered as a one-time infusion in an outpatient setting.
The company initiated a rolling biologics license application submission with the U.S. Food and Drug Administration and anticipates a potential U.S. launch in the first half of 2027, if approved. InvestingPro analysis suggests the stock is currently undervalued, trading below its Fair Value. For deeper insights, investors can access the comprehensive Pro Research Report, available for NTLA and 1,400+ other US equities.
Hereditary angioedema is a rare genetic condition affecting approximately one in 50,000 people, characterized by recurrent swelling attacks. Current treatment options often require chronic administration as frequently as twice per week or daily.
The information is based on a press release statement from Intellia Therapeutics.
In other recent news, Intellia Therapeutics is set to release topline clinical data from its Phase 3 HAELO trial for the CRISPR gene editing candidate lonvoguran ziclumeran, which targets hereditary angioedema. This trial is significant as it represents the first Phase 3 readout for an in vivo CRISPR gene editing candidate. Additionally, Jones Trading upgraded Intellia Therapeutics to a buy rating from hold, citing the FDA’s removal of clinical holds on the MAGNITUDE and MAGNITUDE-2 trials. Brookline Capital Markets reiterated its buy rating on the stock, maintaining a $106 price target, and noted the promising data for NTLA-2002 in hereditary angioedema presented at a recent medical meeting.
Intellia also presented four posters at the American Academy of Allergy, Asthma & Immunology Annual Meeting, focusing on its investigational therapy lonvoguran ziclumeran. The therapy aims to prevent hereditary angioedema attacks by targeting the kallikrein B1 gene. Following the FDA’s lifting of a clinical hold, Citizens raised its price target for Intellia Therapeutics to $28, retaining a Market Outperform rating. These developments highlight ongoing advancements and interest in Intellia’s gene editing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.